Development of cancer Immunotherapy targeting BTLA
| Project/Area Number |
23800043
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Tumor immunology
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
TAMADA Koji 山口大学, 大学院・医学系研究科, 教授 (00615841)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 免疫チェックポイント機構 / 免疫共シグナル分子 / 腫瘍反応性 T リンパ球 / がん免疫療法 / 共シグナル分子 / ＢＴＬＡ / ＨＶＥＭ / 腫瘍免疫学 / BTLA / HVEM |
|---|
| Research Abstract |
This project aims at optimized regulation of immune co-signal functions so as to induce potent anti-tumor immunotherapy. For this purpose, we have generated a fusion protein consisting extracellular domain of BTLA and immunoglobulin Fc region, which could deliver stimulatory co-signal while attenuating inhibitory co-signal simultaneously. Whereas this protein induced T cell activation, its injection led to no apparent anti-tumor effect in animal models. We plan to re-construct this protein in order to increase its immune activity and re-examine anti-tumor effects in vivo.
|
Report
(3 results)
Research Products
(12 results)
